Charles River Laboratories International, Inc. (CRL) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Charles River Laboratories International, Inc. (CRL) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Charles River Laboratories International, Inc. (CRL) stock is N/A over the past 12 months. The 3 year average growth rate is -0.63% and the 5 year cagr is -1.30%. Operating cash flow CAGR measures the compound annual growth rate of the cash Charles River Laboratories International, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
CRL Operating Cash Flow CAGR Chart
Charles River Laboratories International, Inc. (CRL)
CRL Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $734.58M | $737.65M | +$3.07M | +0.42% | +0.42% |
| 2024 | $683.90M | $734.58M | +$50.68M | +7.41% | +7.41% |
| 2023 | $619.64M | $683.90M | +$64.26M | +10.37% | +10.37% |
| 2022 | $760.80M | $619.64M | $-141.16M | -18.55% | -18.55% |
| 2021 | $546.58M | $760.80M | +$214.22M | +39.19% | +39.19% |
| 2020 | $480.94M | $546.58M | +$65.64M | +13.65% | +13.65% |
| 2019 | $441.14M | $480.94M | +$39.80M | +9.02% | +9.02% |
| 2018 | $316.26M | $441.14M | +$124.88M | +39.48% | +39.48% |
| 2017 | $298.32M | $316.26M | +$17.95M | +6.02% | +6.02% |
| 2016 | $286.36M | $298.32M | +$11.96M | +4.18% | +4.18% |
| 2015 | $251.05M | $286.36M | +$35.31M | +14.06% | +14.06% |
| 2014 | $207.14M | $251.05M | +$43.91M | +21.20% | +21.20% |
| 2013 | $207.90M | $207.14M | $-761.00K | -0.37% | -0.37% |
| 2012 | $205.28M | $207.90M | +$2.62M | +1.27% | +1.27% |
| 2011 | $169.01M | $205.28M | +$36.27M | +21.46% | +21.46% |
| 2010 | $225.04M | $169.01M | $-56.03M | -24.90% | -24.90% |
| 2009 | $279.95M | $225.04M | $-54.91M | -19.61% | -19.61% |
| 2008 | $284.25M | $279.95M | $-4.30M | -1.51% | -1.51% |
| 2007 | $164.37M | $284.25M | +$119.88M | +72.93% | +72.93% |
| 2006 | $236.70M | $164.37M | $-72.33M | -30.56% | -30.56% |
| 2005 | $184.83M | $236.70M | +$51.88M | +28.07% | +28.07% |
| 2004 | $123.77M | $184.83M | +$61.06M | +49.34% | +49.34% |
| 2003 | $133.66M | $123.77M | $-9.89M | -7.40% | -7.40% |
| 2002 | $71.30M | $133.66M | +$62.36M | +87.47% | +87.47% |
| 2001 | $33.77M | $71.30M | +$37.53M | +111.14% | +111.14% |
| 2000 | $37.57M | $33.77M | $-3.80M | -10.11% | -10.11% |
| 1999 | $37.38M | $37.57M | +$188.00K | +0.50% | +0.50% |
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster